23andMe Wants to Take Its DNA Tests Mass-MarketBy
For 23andMe, convincing consumers to spit out their DNA has become a race against time. In 2007, when the Silicon Valley startup hit the market with a $999 genetic test offering, it seemed like an esoteric and largely disease-focused product. Now, as rivals hawk DNA tests as a tool for finding dates and detecting drug risks, 23andMe is trying to morph into a more mainstream lifestyle brand.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Tesla Unveils ‘World’s Fastest Production Car’ and Electric Big Rig
- Norway Idea to Exit Oil Stocks Is ‘Shot Heard Around the World’
- Getting a Dog May Save Your Life, Especially If You’re Single
- The Questionable Math Behind Manafort’s Extravagant Home Renovations
- World’s Biggest Wealth Fund Wants Out of Oil and Gas